Researchers at The Wistar Institute took ovarian cancer cells that had survived chemotherapy, removed the cells entirely, and kept only the liquid they had been sitting in. Then they exposed fresh cancer cells to that liquid.
The fresh cells became significantly more likely to detach without ever touching a survivor.
When the team analyzed the liquid, the messenger turned out to be fructose, the same sugar found in fruit and high-fructose corn syrup. Their study, conducted with collaborators at the University of Pittsburgh School of Medicine, published in Nature Aging on July 30.
This is laboratory and animal work. It has not been tested in a single patient, and that belongs at the top rather than the bottom.
The Cells That Stop Dividing but Keep Talking
High-grade serous ovarian cancer, the most common and aggressive form, is treated with platinum-based chemotherapy. Most tumors respond well at first. In most patients, the disease returns, and when it does, it typically spreads through the abdominal cavity. That spread accounts for roughly 90% of deaths from the disease.
The question the team set out to answer was what the cells that survive cisplatin are actually doing during the quiet period. The answer is senescence: they stop dividing but stay metabolically active, releasing a mixture of molecules known collectively as the senescence-associated secretory phenotype.
"Some cancer cells that survive chemotherapy aren't dividing anymore, but they're still biologically active," said Aidan Cole, a postdoctoral fellow in Katherine Aird's lab at Wistar and first author. "Instead, they continue to release molecules that send signals to nearby cells. Our study is among the first to show that a nutrient, in this case fructose, can act as one of those signals."
Nutrients acting as fuel for tumors is well-established biology. Fructose functioning as a message rather than a meal is not.
Cholesterol as Glue
The team traced what happens once a neighboring cell takes up the fructose.
It runs through mitochondrial complex I and an NAD-dependent signaling axis, and the endpoint is suppressed cholesterol production. Cholesterol stabilizes cell membranes and helps anchor cells to one another and to surrounding tissue. As ScienceAlert described, with less cholesterol in their membranes, the cancer cells became less adhesive and more likely to break free.
That is the mechanistic core: not that fructose feeds the tumor, but that it loosens the tumor's grip on itself.
The researchers also tested fructose from outside the system. In mice, a high-fructose diet increased dissemination of ovarian cancer, which is a genuine in vivo dietary result rather than a cell-culture artifact.
Aird drew a distinction worth preserving. "When people eat fruit or other natural foods, the fructose is only in a small amount, and other components of those foods slow digestion to limit a sugar spike," she told Newsweek. "In contrast, fructose from processed foods is at very high concentrations and is rapidly processed by the body."
The Statin Question the Researchers Raised Themselves
The cholesterol link led directly to an uncomfortable implication, and the team raised it rather than waiting for someone else to.
"We haven't tested this effect in patients yet, but it raises questions about combining cholesterol-lowering drugs with chemotherapy, especially since ovarian cancer is most common in postmenopausal women who are often already on statins," Aird said.
Read the first clause as carefully as the rest. That is a hypothesis flagged for investigation, not a warning. The study did not test statins in patients, did not measure cancer outcomes in statin users, and produced no evidence that anyone should stop a prescribed cholesterol medication. Statins have substantial proven cardiovascular benefit, and dropping one on the strength of a preclinical cancer paper would be a poor trade.
The team is also examining whether the mechanism extends beyond ovarian cancer. Aird named pancreatic, colon, and liver cancer as candidates, while cautioning that the effect cannot be called universal yet.
What Preclinical Actually Means Here
The gap between a mechanism in a dish and a change in patient care is where most promising cancer findings end.
This work does not show that dietary fructose affects survival, recurrence, or spread in people. It does not establish that human tumors, which sit in a far more complex environment than a culture plate or a mouse, behave the same way. And no dietary recommendation follows from it.
What it does provide is a testable mechanism for something clinicians have long observed without explaining: why ovarian cancer so reliably returns and spreads after treatment that initially appeared to work. If chemotherapy-surviving cells are actively signaling rather than lying dormant, that changes what a post-treatment intervention would need to target.
Anyone in treatment for ovarian cancer should raise questions about diet or medications with their oncology team rather than acting on early-stage research.
Key Questions Answered
What did the researchers find?
Ovarian cancer cells that survived cisplatin released fructose, which made neighboring tumor cells more capable of detaching and spreading in cells and in mice.
How does fructose have that effect?
It works through mitochondrial complex I and an NAD-dependent pathway to suppress cholesterol production in the receiving cell. Cholesterol helps cells stay attached, so lower levels weaken those bonds.
Does eating fructose make cancer spread?
In mice, a high-fructose diet increased dissemination. No effect of dietary fructose on human cancer outcomes was measured, and no dietary recommendation follows from this study.
Should ovarian cancer patients stop taking statins?
No. The researchers raised the interaction as a question worth studying. No evidence of harm in patients was produced, and statins have proven cardiovascular benefit.
Why does ovarian cancer spread matter so much?
Metastasis through the abdominal cavity accounts for roughly 90% of deaths from the disease, even though most tumors initially respond to platinum chemotherapy.
Could this apply to other cancers?
The researchers are investigating pancreatic, colon, and liver cancer, but say the effect cannot be called universal yet.
